Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 189

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain

Open access
Näslund, Jan, Thyberg, Johan, Tjernberg, Lars O., Wernstedt, Christer, Karlström, Anders R., Bogdanovic, Nenad, Gandy, Samuel E., Lannfelt, Lars, Terenius, Lars, Nordstedt, Christer·1995·Neuron

Abstract

Genetic evidence suggests a role for apolipoprotein E (apoE) in Alzheimer's disease (AD) amyloidogenesis. Here, amyloid-associated apoE from 32 AD patients was purified and characterized. We found that brain amyloid-associated apoE apparently exists not as free molecules but as complexes with polymers of the amyloid beta peptide (A beta). Brain A beta-apoE complexes were detected irrespective of the apoE genotype, and similar complexes could be mimicked in vitro. The fine structure of purified A beta-apoE complexes was fibrillar, and immunogold labeling revealed apoE immunoreactivity along the fibrils. Thus, we conclude that A beta-apoE complexes are principal components of AD-associated brain amyloid and that the data presented here support a role for apoE in the pathogenesis of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/0896-6273(95)90079-9

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 27

  1. Abraham, 1988, Immunochemical identification of the serine protease inhibitor α1-antichymotrypsin in the brain amyloid deposits of Alzheimers disease, Cell, 52, 487, 10.1016/0092-8674(88)90462-X · DOI · Paper page
  2. Berr, 1994, Apolipoprotein E allele ε4 is linked to increased deposition of the amyloid β-peptide (A-β) in cases with or without Alzheimer's disease, Neurosci. Lett., 178, 221, 10.1016/0304-3940(94)90763-3 · DOI
  3. Cardin, 1986, Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains, Biochem. Biophys. Res. Commun., 134, 783, 10.1016/S0006-291X(86)80489-2 · DOI
  4. Coria, 1988, Isolation and characterization of amyloid P component from Alzheimers disease and other types of cerebral amyloidosis, Lab. Invest., 58, 454
  5. Davies, 1993, Is the “preamyloid” of diffuse plaques in Alzheimer's disease really nonfibrillar?, Am. J. Pathol., 143, 1594
  6. Glenner, 1980, Amyloid deposits and amyloidosis: the β-fibrilloses (first of two parts), J. Engl. J. Med., 302, 1283, 10.1056/NEJM198006053022305 · DOI · Paper page
  7. Glenner, 1984, Alzheimers disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein, Biochem. Biophys. Res. Commun., 120, 885, 10.1016/S0006-291X(84)80190-4 · DOI · Paper page
  8. Heukeshoven, 1985, Characterization of a solvent system for separation of water-insoluble Poliovirus proteins by reversed-phase high-performance liquid chromatography, J. Chromatogr., 326, 91, 10.1016/S0021-9673(01)87434-3 · DOI
  9. Jarret, 1993, Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie?, Cell, 73, 1055, 10.1016/0092-8674(93)90635-4 · DOI · Paper page
  10. Kida, 1994, Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain, Neurosci. Lett., 167, 73, 10.1016/0304-3940(94)91030-8 · DOI
  11. Kim, 1988, Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide, Neurosci. Res. Commun., 2, 121
  12. Kim, 1990, Detection and quantitation of amyloid β-peptide with two monoclonal antibodies, Neurosci. Res. Commun., 7, 113
  13. Mayeux, 1993, The apolipoprotein E epsilon 4 allele in patients with Alzheimer's disease, Ann. Neurol., 34, 752, 10.1002/ana.410340527 · DOI · Paper page
  14. McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
  15. Milne, 1981, Characterization of monoclonal antibodies against human apolipoprotein E, J. Clin. Invest, 68, 111, 10.1172/JCI110225 · DOI
  16. Namba, 1991, Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease, Brain. Res., 541, 163, 10.1016/0006-8993(91)91092-F · DOI · Paper page
  17. Nordstedt, 1994, The Alzheimer Aβ peptide develops protease resistance in association with its polymerization into fibrils, J. Biol. Chem., 269, 30773, 10.1016/S0021-9258(18)47347-4 · DOI
  18. Peacock, 1994, ApoE ε4 allelic association with Alzheimer's disease: independent confirmation using denaturing gradient gel electrophoresis, Neurology, 44, 339, 10.1212/WNL.44.2.339 · DOI
  19. Rebeck, 1993, Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions, Neuron, 11, 575, 10.1016/0896-6273(93)90070-8 · DOI · Paper page
  20. Rozemuller, 1989, A4 protein in Alzheimer's disease: primary and secondary cellular events in extracellular amyloid deposition, J. Neuropathol. Exp. Neurol., 48, 674, 10.1097/00005072-198911000-00009 · DOI · Paper page
  21. Selkoe, 1991, The molecular pathology of Alzheimeis disease, Neuron, 6, 487, 10.1016/0896-6273(91)90052-2 · DOI · Paper page
  22. Snow, 1990, Early accumulation of heparin sulfate in neurons and in the β-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome, Am. J. Pathol., 137, 1253
  23. Weisgraber, 1983, The receptor-binding domain of human apolipoprotein E, J. Biol. Chem., 258, 12348, 10.1016/S0021-9258(17)44181-0 · DOI · Paper page
  24. Wenham, 1991, Apolipoprotein E genotyping by one-stage PCR, Lancet, 337, 1158, 10.1016/0140-6736(91)92823-K · DOI · Paper page
  25. Wisniewski, 1992, Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid, Neurosci. Lett., 135, 235, 10.1016/0304-3940(92)90444-C · DOI · Paper page
  26. Wisniewski, 1994, Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro, Am. J. Pathol., 145, 1030
  27. Wunderlich, 1992, Use of recombinant fusion proteins for generation and rapid characterization of monoclonal antibodies. Application to the Kunitz domain of human R amyloid precursor protein, J. Immunol. Meth., 147, 1, 10.1016/S0022-1759(12)80022-6 · DOI

Cited by

See all 189

Metadata

Authors
Näslund, J., Thyberg, J., Tjernberg, L. O., Wernstedt, C., Karlström, A. R., Bogdanovic, N., Gandy, S. E., Lannfelt, L., Terenius, L., & Nordstedt, C.
Venue
Neuron
Publisher
Elsevier BV
Published
1995-07
Volume
15
Issue
1
Pages
219-228
ISSN
0896-6273 (ISSN-L)
OpenAlex
W2048509804
Cited by
189
References
17
FWCI
8.66
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
  • Svenska Sällskapet för Medicinsk Forskning
  • Starr Foundation
  • National Institutes of Health (HL49571-01, AG-11506)
  • Medicinska ForskningsrÃ¥det

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. https://app.cochat.ai/papers/10.1016/0896-6273(95)90079-9
The paper
Näslund, J., Thyberg, J., Tjernberg, L. O., Wernstedt, C., Karlström, A. R., Bogdanovic, N., Gandy, S. E., Lannfelt, L., Terenius, L., & Nordstedt, C. (1995). Characterization of stable complexes involving apolipoprotein E and the amyloid β peptide in Alzheimer's disease brain. Neuron. https://doi.org/10.1016/0896-6273(95)90079-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.